Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza for neuropathic pain from arteriovenous fistulae in end stage renal failure
2014-002266-71Phase 4Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capsaicin in Neuralgia and end-stage kidney disease (ESKD), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Change in pain (VAS) at 12 weeks. Started Jun 2019; status: terminated.
02
Drugs
capsaicin
03
Conditions
Neuralgiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2014-002266-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002266-71.